- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 03.04. | AEON Biopharma Inc: AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards | 332 | GlobeNewswire (Europe) | IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar... ► Artikel lesen | |
| 03.04. | AEON Biopharma receives additional NYSE American non-compliance notice | 2 | Seeking Alpha | ||
| 30.03. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | AEON Biopharma reports biosimilar progress, secures financing | 1 | Investing.com | ||
| 30.03. | AEON Biopharma Inc: AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program | 109 | GlobeNewswire (Europe) | - Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX - - Reported positive FDA BPD Type 2a... ► Artikel lesen | |
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 25.03. | AEON Biopharma receives FDA feedback on botulinum toxin biosimilar | 3 | Investing.com | ||
| 09.03. | AEON Biopharma names John Bencich as chief financial officer | 2 | Investing.com | ||
| 09.03. | AEON Biopharma beruft John Bencich zum neuen Finanzvorstand | 2 | Investing.com Deutsch | ||
| 09.03. | AEON Biopharma Inc: AEON Biopharma Appoints John Bencich as Chief Financial Officer | 817 | GlobeNewswire (Europe) | IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar... ► Artikel lesen | |
| 09.03. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.01. | AEON Biopharma Completes BPD Type 2a Meeting With FDA | - | RTTNews | ||
| 21.01. | Aeon Biopharma: Aktie gibt nach FDA-Gespräch und Umschuldung nach | 1 | Investing.com Deutsch | ||
| 21.01. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | AEON Biopharma Inc: AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions | 634 | GlobeNewswire (Europe) | - AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today... ► Artikel lesen | |
| 12.01. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.25 | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 15.12.25 | AEON Biopharma announces execution of exchange agreement with Daewoong Pharmaceutical | 1 | Seeking Alpha | ||
| 15.12.25 | AEON Biopharma Inc: AEON Biopharma Announces Execution of Exchange Agreement with Daewoong | 673 | GlobeNewswire (Europe) | - AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise... ► Artikel lesen | |
| 15.12.25 | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MAINZ BIOMED | 0,487 | -3,45 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| TEMPUS AI | 47,510 | +0,07 % | Tempus AI Expands Strategic Partnership Amid Oncology Boom | ||
| ABIVAX | 104,00 | +0,97 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,006 | +50,00 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors | MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 5,290 | -6,54 % | EQS-News: Benzinga: Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | EQS-News: Benzinga
/ Key word(s): Healthcare
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,010 | +2,42 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| KAILERA THERAPEUTICS | 26,010 | 0,00 % | Heißes Adipositas-IPO: Kailera will es mit den Großen aufnehmen | Der wachstumsstarke Markt für Appetitzügler ist heiß umkämpft. Immer mehr Player streben in den Markt, um sich mittel- bis langfristig ein Stück vom milliardenschweren Kuchen abzuschneiden. Auch Kailera... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 22,460 | 0,00 % | Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 342,50 | +6,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| QIAGEN | 35,350 | +1,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,250 | +2,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TREVI THERAPEUTICS | 15,210 | +4,61 % | Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session | ||
| BIONTECH | 87,55 | +0,11 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| CG ONCOLOGY | 73,44 | +10,67 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| SUMMIT THERAPEUTICS | 25,140 | +2,95 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data |
AEON BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,67 % bei einem Aktienkurs von 1,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.